Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Ligand Pharmaceuticals (LGND) Non-Current Debt (2025)

Historic Non-Current Debt for Ligand Pharmaceuticals (LGND) over the last 6 years, with Q3 2025 value amounting to $445.5 million.

Ligand Pharmaceuticals' Non-Current Debt changed N/A to $445.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year change of. This contributed to the annual value of $205.4 million for FY2015, which is 483.08% up from last year.
Per Ligand Pharmaceuticals' latest filing, its Non-Current Debt stood at $445.5 million for Q3 2025.
In the past 5 years, Ligand Pharmaceuticals' Non-Current Debt ranged from a high of $445.5 million in Q3 2025 and a low of $445.5 million during Q3 2025